Clinical Trial Update: Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer [Phase 2]

View source ↗

Summary

Phase II study of ramucirumab in combination with chemotherapy for metastatic gastric/gastroesophageal junction cancer was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Ramucirumab (ramucirumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Gastric Cancer, Gastroesophageal Junction Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-01-07